Research | Page 62 of 638 | SpiritIndia.com

Lung Cancer :: Blood protein detects lung cancer at earliest stage

Biopharmaceutical researchers have found a protein in blood they say is linked to all stages of lung cancer but which rarely shows up in the blood of people without the disease. Testing for this protein might help physicians decide whether smokers or others at high risk for lung cancer should be referred for lung imaging, say investigators, who presented their findings today in Atlanta, Georgia at the American Association for Cancer Research’s second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

Vaccine :: Sanofi Pasteur’s H5N1 Influenza Vaccine achieves high immune response at low dosage

Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, announced data showing that its new investigational H5N1 pandemic influenza vaccine containing a proprietary adjuvant achieved a high immune response at the lowest dose of H5N1 antigen reported to date.

Health :: UT Southwestern earns $34M NIH grant to foster patient-oriented research

UT Southwestern Medical Center will receive $34 million from the National Institutes of Health to lead a wide-ranging collaborative initiative aimed at speeding the transfer of laboratory discoveries to new therapies that improve human health.

Heart :: Merck sued for Medicaid Fraud over Vioxx, hiding heart risks

Attorney General Andrew M. Cuomo and New York City Mayor Michael Bloomberg filed a joint lawsuit against the maker of Vioxx for misrepresenting the dangers the drug posed to its users.

Osteoporosis :: Aclasta Reclast prevents additional fractures in hip fracture patients with osteoporosis

Results of the first-ever clinical study in patients with osteoporosis who suffered a hip fracture show that a once-yearly infusion of Aclasta®/Reclast® (zoledronic acid 5 mg)[*] reduced the risk of subsequent fractures by 35% compared to patients treated with placebo.

Parkinson’s Disease :: Gene abnormality tied to getting Parkinson’s disease at a younger age

People with a certain gene mutation are more likely to get Parkinson’s disease before the age of 50 compared to those without the gene abnormality, according to a study published in the September 18, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology.

Genetic :: FDA Clears Genetic Lab Test for Warfarin Sensitivity

The U.S. Food and Drug Administration cleared for marketing a new genetic test that will help physicians assess whether a patient may be especially sensitive to the blood-thinning drug warfarin (Coumadin), which is used to prevent potentially fatal clots in blood vessels.

Brain :: Scientists identify fundamental brain defect, probable drug target in fragile X syndrome

Scientists have discovered how the gene mutation responsible for fragile X syndrome — the most common inherited form of mental retardation — alters the way brain cells communicate. In neurons cultured from laboratory rats, the scientists also were able to reverse the effects of the mutation using a drug targeted to the specific site in an upstream pathway of the defect. The finding could lead to the development of human therapies for this previously untreatable condition.

Sperm :: New cell death pathway involved in sperm development

New research from Rockefeller University and the Howard Hughes Medical Institute uncovers a new pathway that regulates caspase activity in Drosophila sperm, a finding that may provide new opportunities to develop drugs that can alter cell death for therapeutic purposes.

RNA :: Mechanism for the in-vivo transport of siRNA

RNA interference, a natural mechanism that inhibits the gene expression of individual genes in eukaryotic cells, is a major topic in modern biology. However, their potential was usable to only a limited extent in mammals because the mechanism for the uptake of small RNAs was unknown up to now. ETH Zurich biologists have now clarified this, which also opens the door for therapies based on this mechanism.